Decrease (-) Restore Default Increase (+)

Clinical Trials

Topic   Allergy and Immunology
Title   Patients diagnosed with Acute Hereditary Angioedema
Summary   The purpose of this study is to evaluate immunogenicity (ability to trigger an immune response) and hypersensitivity (undesirable reaction produced by the immune system) upon exposure to an FDA approved medication for patients who suffer from sudden HAE attacks.
Description   NYU Winthrop Hospital Clinical Trials Center is Seeking participants that are at least 16 years of age and have been diagnosed with Acute Hereditary Angioedema. Hereditary Angioedema (HAE) is a very rare and potentially life-threatening genetic condition that occurs in about 1 in 10,000 to 1 in 50,000 people. HAE symptoms include episodes of swelling in various body parts including the hands, feet, face and airway. Patients may also have bouts of excruciating abdominal pain, nausea and vomiting that is caused by swelling in the intestinal wall. Airway swelling is particularly dangerous and can lead to death by asphyxiation
IRB┬áNumber   -
Inclusion/Notes   To be eligible for this clinical research study, you must be 16 years old or older. Have been diagnosed with Acute Hereditary Angioedema
Principal┬áName   Mark Davis-Lorton, MD
Email   clinicaltrials@nyuwinthrop.org
Phone   516-663-9582